Navigation Links
BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury

HERNDON, Va., Sept. 8 /PRNewswire/ -- BHR Pharma, LLC (BHR) announced today that it will initiate a global, Phase 3, multi-center pivotal trial ( to evaluate the effectiveness of its proprietary BHR-100 intravenous progesterone infusion product as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients in early 2010.

BHR will enroll approximately 1,200 patients with severe (Glasgow Coma Scale scores of 4-8), closed-head trauma TBI at 100-120 medical centers in the United States, Europe, Israel and additional countries.

Randomized patients will receive a five-day (120-hour) intravenous infusion of progesterone or placebo. Unlike intravenous progesterone infusions described in the medical literature, BHR-100 is a ready-to-use infusion designed to meet all U.S. Food and Drug Administration approval requirements.

BHR is collaborating with the American Brain Injury Consortium (ABIC) and the European Brain Injury Consortium (EBIC) to identify the trial sites and help design the clinical study. PRA International is the Contract Research Organization for the trial.

TBI is a non-degenerative, non-congenital insult to the brain from an external mechanical force, possibly leading to permanent or temporary impairments of cognitive, physical and psychosocial functions with an associated diminished or altered state of consciousness.

Approximately 1.5 million Americans per year suffer a traumatic brain injury, resulting in 50,000 deaths, 235,000 hospitalizations and 80,000 cases of long-term disability. Incidence of TBI in all industrialized countries is comparable to that in the U.S., with estimates ranging from 150 to more than 300 per 100,000. There are approximately 66,000 deaths annually attributed to TBI in Europe.

The leading cause of TBI in the world is road traffic accidents, accounting for 40-50 percent of the hospitalizations for TBI.

There are currently no approved medications to improve outcomes following TBI.

The SyNAPSe study will build on promising results achieved in several previous clinical trials that demonstrated a mortality benefit and improved functional outcomes in TBI patients treated with progesterone. BHR has exclusively licensed the rights to a patent family claiming the use of progesterone to treat traumatic brain injury, along with preclinical and clinical data from a Phase 2 TBI study.

About BHR

Founded in January 2008, BHR Pharma, LLC ( is a pharmaceutical research and development (R&D) company located near Washington, DC. BHR is committed to bringing to market specialty treatments that employ non-oral delivery systems, with an emphasis on unmet and underserved medical needs.

A wholly owned subsidiary of Besins Healthcare SA (, which markets healthcare products in 93 countries, BHR manages all of Besins' global R&D activities. Those activities primarily leverage proprietary parenteral drug formulations, including the Enhanced Hydroalcoholic Gel (EHG((R))) technology pioneered and commercially launched by Besins in 1975.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
2. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
3. Vion Pharmaceuticals Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
4. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA
5. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
6. Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009
7. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
8. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
9. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
10. NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
11. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
Post Your Comments:
(Date:10/4/2017)...  According to the Centers for Disease Control and Prevention (CDC), ... Urgent Care is helping communities across Massachusetts , ... offering no-cost* flu shots through the end of the month. ... regulations. ... a flu shot is by the end of October, according to the ...
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 /PRNewswire/ ... health and big data solutions, today announced that its MyDario product is ... your local TV listings for when The Dr. Oz Show airs in ... The nine-time ... month. ...
Breaking Medicine Technology:
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
Breaking Medicine News(10 mins):